TY - JOUR
T1 - The long-term sequelae of COVID-19
T2 - an international consensus on research priorities for patients with pre-existing and new-onset airways disease
AU - International COVID-19 Airways Diseases Group
AU - Adeloye, Davies
AU - Elneima, Omer
AU - Daines, Luke
AU - Poinasamy, Krisnah
AU - Quint, Jennifer K.
AU - Walker, Samantha
AU - Brightling, Chris E.
AU - Siddiqui, Salman
AU - Hurst, John R.
AU - Chalmers, James D.
AU - Pfeffer, Paul E.
AU - Novotny, Petr
AU - Drake, Thomas M.
AU - Heaney, Liam G.
AU - Rudan, Igor
AU - Sheikh, Aziz
AU - De Soyza, Anthony
AU - Abdollahi, Mohammad
AU - Agarwal, Dhiraj
AU - Al-Lehebi, Riyad
AU - Barnes, Peter J.
AU - Bayry, Jagadeesh
AU - Bonay, Marcel
AU - Bont, Louis J.
AU - Bourdin, Arnaud
AU - Brown, Thomas
AU - Caramori, Gaetano
AU - Chan, Amy Hai Yan
AU - Dockrell, David H.
AU - Doe, Simon
AU - Duckers, Jamie
AU - D'Urzo, Anthony
AU - Ekström, Magnus
AU - Esteban, Cristóbal
AU - Greene, Catherine M.
AU - Gupta, Atul
AU - Ingram, Jennifer L.
AU - Khoo, Ee Ming
AU - Ko, Fanny Wai San
AU - Koppelman, Gerard H.
AU - Lipworth, Brian J.
AU - Lisspers, Karin
AU - Loebinger, Michael
AU - Lopez-Campos, Jose Luis
AU - Maddocks, Matthew
AU - Mannino, David
AU - Martinez-Garcia, Miguel A.
AU - Mcnamara, Renae
AU - Miravitlles, Marc
AU - Rhee, Chin Kook
N1 - Publisher Copyright:
© 2021 Elsevier Ltd
PY - 2021/12
Y1 - 2021/12
N2 - Persistent ill health after acute COVID-19—referred to as long COVID, the post-acute COVID-19 syndrome, or the post-COVID-19 condition—has emerged as a major concern. We undertook an international consensus exercise to identify research priorities with the aim of understanding the long-term effects of acute COVID-19, with a focus on people with pre-existing airways disease and the occurrence of new-onset airways disease and associated symptoms. 202 international experts were invited to submit a minimum of three research ideas. After a two-phase internal review process, a final list of 98 research topics was scored by 48 experts. Patients with pre-existing or post-COVID-19 airways disease contributed to the exercise by weighting selected criteria. The highest-ranked research idea focused on investigation of the relationship between prognostic scores at hospital admission and morbidity at 3 months and 12 months after hospital discharge in patients with and without pre-existing airways disease. High priority was also assigned to comparisons of the prevalence and severity of post-COVID-19 fatigue, sarcopenia, anxiety, depression, and risk of future cardiovascular complications in patients with and without pre-existing airways disease. Our approach has enabled development of a set of priorities that could inform future research studies and funding decisions. This prioritisation process could also be adapted to other, non-respiratory aspects of long COVID.
AB - Persistent ill health after acute COVID-19—referred to as long COVID, the post-acute COVID-19 syndrome, or the post-COVID-19 condition—has emerged as a major concern. We undertook an international consensus exercise to identify research priorities with the aim of understanding the long-term effects of acute COVID-19, with a focus on people with pre-existing airways disease and the occurrence of new-onset airways disease and associated symptoms. 202 international experts were invited to submit a minimum of three research ideas. After a two-phase internal review process, a final list of 98 research topics was scored by 48 experts. Patients with pre-existing or post-COVID-19 airways disease contributed to the exercise by weighting selected criteria. The highest-ranked research idea focused on investigation of the relationship between prognostic scores at hospital admission and morbidity at 3 months and 12 months after hospital discharge in patients with and without pre-existing airways disease. High priority was also assigned to comparisons of the prevalence and severity of post-COVID-19 fatigue, sarcopenia, anxiety, depression, and risk of future cardiovascular complications in patients with and without pre-existing airways disease. Our approach has enabled development of a set of priorities that could inform future research studies and funding decisions. This prioritisation process could also be adapted to other, non-respiratory aspects of long COVID.
UR - http://www.scopus.com/inward/record.url?scp=85122545951&partnerID=8YFLogxK
U2 - 10.1016/S2213-2600(21)00286-1
DO - 10.1016/S2213-2600(21)00286-1
M3 - Review article
C2 - 34416191
AN - SCOPUS:85122545951
SN - 2213-2600
VL - 9
SP - 1467
EP - 1478
JO - The Lancet Respiratory Medicine
JF - The Lancet Respiratory Medicine
IS - 12
ER -